Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine,General Medicine
Reference17 articles.
1. Prevalence of psoriasis in China: a population-based study in six cities;Ding;Eur J Dermatol,2012
2. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis;Blauvelt;Clin Rev Allergy Immunol,2018
3. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis;Cai;Chin Med J,2020
4. Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients;Huang;Eur J Dermatol,2020
5. Effect of body weight on risk-benefit and dosing regimen recommendation of secukinumab for the treatment of moderate to severe moderate-to-severe plaque psoriasis;Lee;Clin Pharmacol Ther,2019
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Olink Proteomics for the Identification of Biomarkers for Early Diagnosis of Postmenopausal Osteoporosis;Journal of Proteome Research;2024-09-03
2. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects;Drug Design, Development and Therapy;2024-08
3. Case report and brief literature review: possible association of secukinumab with Guillain–Barré syndrome in psoriasis;Frontiers in Immunology;2024-06-28
4. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis;British Journal of Dermatology;2024-02-15
5. Use of biologics in patients with psoriasis – A retrospective analysis based on real‐world data;Skin Research and Technology;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3